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Altered pharmacokinetics and pharmacodynamics associated with 
ageing may contribute to drugs being classified as inappropriate for 
use in older adults.[1] With the number of older and very old people 
increasing rapidly,[2] inappropriate medicine prescribing in the older 
population is becoming a well-recognised problem.[3] Developing 
countries such as South Africa (SA) are not exempt from the effects 
of an ageing population. For instance, the pensioner ratio in SA 
increased from 5.9% in 2001 to 7.3% in 2014,[4] with approximately 
half of older patients in the private health sector of SA suffering 
from more than one chronic disease, some being diagnosed with up 
to 11 conditions.[5] There has been an increase in the complexity of 
medication regimens used to treat older patients, and they usually 
have multiple prescribers. Careful planning and knowledge of the 
ageing process and the drugs prescribed are essential in prescribing 
for older patients, as they are at an increased risk of developing drug-
related problems.[6]
Several tools and criteria to improve rational medicine use in older 
patients are available. These can be grouped into implicit and explicit 
tools, and tools based on a combination of these two. The Beers 
criteria list is one of the most frequently applied and adopted explicit 
screening tools to assess potentially inappropriate prescriptions 
(PIPs). It has been adopted by numerous medical aid groups 
and administrators to pinpoint older patients with an increased 
probability of experiencing negative outcomes related to PIP, and it 
has shown to be a useful tool for assessing PIP in large populations.[1]
A review of US-based studies[7] indicated that almost 40% of 
people living in care facilities for the aged received inappropriate 
prescriptions, and almost half as much was seen in community-
dwelling people aged ≥65 years. A similar Australian-based study[8] 
found that almost 20% of patients aged ≥70 years had at least one 
inappropriate prescription during a 6-month period. Similar to these, 
an earlier study conducted in SA to identify potentially inappropriate 
medicine items prescribed to older patients showed that 30% of 
prescriptions (n=6 410) included at least one potentially inappropriate 
item.[9] A common finding is that older female patients are more 
likely than older males to be prescribed potentially inappropriate 
medication.[9] Some of the most common potentially inappropriate 
medicine items prescribed are those acting on the cardiovascular 
system, psychotropic agents and neuroleptic agents, especially those 
for neuropathic pain. Specific medicine items include amitriptyline, 
benzodiazepines, doxazosin, proton-pump inhibitors, non-steroidal 
anti-inflammatory agents (NSAIDs), digoxin, antihistamines and 
oestrogen (only oral and patch formulations).
Objective
Our study focused only on the private health sector of SA, which 
comprises approximately 16% of the country’s total health sector. 
In December 2014, the total number of medical aid beneficiaries 
was 8.81 million, which consisted of more female (52.5%) than male 
(47.5%) beneficiaries.[4] Although the private sector serves almost 
a quarter of the SA population, data on the utilisation of medicine 
items in the private sector are difficult to access as most of the 
medical aid administrators regard such data as proprietary. The 
general objective of the study was to investigate medicine prescribing 
patterns for older patients in the private health sector of SA utilising 
the 2012-Beers criteria list[10] for PIPs.
Method
Design and data source
A cross-sectional analysis was conducted using a database obtained 
from a well-known SA pharmaceutical benefit management company 
(PBM). At the time, the PBM used had approximately 22 years of 
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service excellence and more than 1.6 million 
South Africans were benefiting from its 
services. The company provided services to 
35 medical aid schemes and five capitation 
provider clients administered by 15 different 
healthcare administrators.[4] At the time of 
writing, the PBM was linked up to all SA’s 
pharmacies and 98% of all dispensing doctors.
The database for the period 1 January - 31 
December 2013 con tained pharmaceutical 
claims information for a total of 8 776 279 
patients. A total of 103 420 patients on 
the database were aged ≥65 years (44 343 
men, 59 077 women), representing 2.5% 
of all people aged ≥60 years with medical 
aid coverage across SA during 2013.[11] We 
queried data fields for patient demographic 
information (sex and date of birth), and 
pertinent prescription information (drug 
trade name, strength, how many days’ supply, 
quantity and treatment date). Date of birth 
and treatment date were used to calculate the 
age of patients on the day of treatment.
Assessment of PIP
The 2012-Beers criteria list[10] was used to 
identify PIPs of medicine items among older 
patients by counting the number of drugs on 
the Beers criteria list per prescription. Some 
drugs listed in the 2012-Beers criteria are 
marketed under different names in SA. For 
example, mepiridine is known as pethidine, 
scopolamine as hyoscine and phenobarbital 
as phenobarbitone. Any item listed in the 
2012-Beers criteria that was not available 
in SA at the time of the study was excluded.
Statistical analysis
Variables were characterised using 95% 
confi dence intervals (CIs), descriptive statis-
tics such as proportions/ratios for cate-
gorical varia bles, and means and standard 
deviations (SDs) for continuous variables. An 
independent two-sample t-test (assuming 
unequal variances) was used to assess the 
statistical significance of the age difference 
between men and women. The χ2 test was 
performed to determine the association 
between the prevalence of the Beers criteria 
list items and gender or age group. Because 
statistical significance tests yielded small 
p-values (indicating significance), in most 
tests we focused our interpretation on effect 
sizes, which are independent of units and 
sample size. Cohen’s d-value was used to 
evaluate mean differences between groups 
(with significance defined as a level of at least 
0.8), and Cramér’s V statistic (defined as a 
level of at least 0.5) was used for associations 
between categorical variables. Statistical 
analyses were performed using SAS software, 
version 9.3 (SAS, USA).
Results
Study population characteristics
A total of 103 420 patients aged ≥65 years 
(male/female ratio 1:1.3) were included in 
the study. Their characteristics are shown 
in  Table 1. There was no difference in 
the mean age of female and male patients 
(p<0.001; Cohen’s d=0.10).
A total of 1  544 268 prescriptions were 
claimed for older patients, at an average of 
14.9  (SD  9.5) per patient (95% CI 14.87 - 
14.99). Women received more prescriptions 
than men (58.6% v. 41.0%), but there was no 
difference between the sexes in terms of the 
average number of prescriptions claimed per 
patient (p<0.001; Cohen’s d=0.09). A total 
number of 4 231 014 drugs were prescribed, 
of which 2 494 560 (59.0%) were prescribed 
to women. A mean of 2.7 drugs (SD 2.1) 
(95% CI 2.73 - 2.74) were claimed per pre-
scription (median two drugs), with no 
difference in the average number of drugs 
per prescription between the sexes (p<0.001; 
Cohen’s d=0.02).
Potentially inappropriate 
prescribing as determined by the 
2012-Beers criteria
A total of 102 of the 143 2012-Beers criteria 
items (71.3%) were available in SA at the 
time of the study and therefore utilised to 
identify PIPs. Application of these criteria 
to the claims data identified 562 852 
potentially inappropriate medicine items 
(13.0%) prescribed to a total of 71 206 
patients (68.9%). The majority of these 
patients (37.2%) received one potentially 
inappropriate item, 26.1% received two 
and 16.2% received three. A further 10.7% 
(n=7 646) received five or more potentially 
inappropriate items.
As shown in Table 2, significantly more 
women (72.3%) received potentially inap-
propriate drugs than men (64.3%) (p<0.001). 
However, this difference in prevalence was 
not practically significant (Cramér’s V=0.06). 
There  was also no differ ence between the 
sexes in terms of the average number of 
potentially inappropriate items prescribed 
per patient (p<0.001; Cohen’s d=0.16). PIPs 
decreased overall with an increase in age. 
However, the differences between the age 
groups in terms of the prevalence of pre-
scribing of inappropriate medicine items 
were also not practically significant (p<0.001; 
Cramér’s V=0.04).
The most frequently potentially inappro-
priately prescribed item was oestrogen (oral 
and patch formulations) (Table 3), pre scribed 
in 69 894 of the patients (12.4%), followed 
by meloxicam (n=41 030, 7.3%), amitripty-
line and combinations thereof (n=36 509, 
6.5%), diclofenac (n=36 062, 6.4%), ibupro-
fen (n=34 162, 6.1%), alprazo lam (n=29 896, 
5.3%), meprobamate and combin ations 
thereof (n=27 894, 5.0%), sliding-scale insu-
lin (n=18 715, 3.3%), amiodarone (n=17 433, 
3.1%) and doxazosin (n=14 816, 2.6%). The 
χ2 analysis showed that  for oestrogen (oral 
and patch formula tions), women received 
significantly more prescriptions than men 
(p<0.001); this associa tion was moderate 
(Cramér’s V=0.27). It also indicated that for 
both sliding-scale insulin (p<0.001; Cramér’s 
V=0.11) and doxazosin (p<0.001; Cramér’s 
V=0.13) men received significantly more 
prescriptions than women. The association 
for both of these items were small. For the 
Table 1. Patient characteristics
Demographics
Total study 
population Female Male
Patients, N (%) 103 420 59 077 (57.1) 44 343 (42.9)
Age (yr), mean (SD) (95% CI) 74.0 (6.7)
(73.9 - 74.0)
74.3 (6.9)
(74.2 - 74.3)
73.6 (6.5)
(73.5 - 73.6)
Age group (yr), n (%)
65≥ age ≤68 23 027 (22.3) 12 615 (12.2) 10 412 (10.1)
68< age ≤72 25 066 (24.2) 13 981 (13.5) 11 085 (10.7)
72< age ≤78 28 604 (27.7) 16 277 (15.7) 12 327 (11.9)
Age >78 26 723 (25.8) 16 204 (15.7) 10 519 (10.2)
Prescriptions, n (%) 1 544 268 905 582 (58.6) 638 686 (41.4)
Prescriptions per patient, mean (SD) 
(95% CI)
14.9 (9.5)
(14.87 - 14.99)
15.3 (9.6)
(15.25 - 15.41)
14.4 (9.4)
(14.32 - 14.49)
Drugs prescribed, n (%) 4 231 014 2 494 560 (59.0) 1 736 454 (41.0)
Drugs per prescription, mean (SD) 
(95% CI)
2.74 (2.07)
(2.73 - 2.74)
2.76 (2.08)
(2.75 - 2.76)
2.72 (2.05)
(2.71 - 2.72)
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other items forming part of the top 10 most frequently prescribed 
items (i.e. meloxicam, amitriptyline, diclofenac, ibuprofen, alpra-
zolam, meprobamate and amiodarone), there was no significant dif-
ference between the sexes (Table 3).
General practitioners prescribed the largest number of inappro-
priate medicine items to the older population (70.7%), followed 
by the specialist group (15.7%), pharmacists (9.0%) and ‘other’, 
which included psychiatrists, radiologists, oncologists and surgeons 
(4.7%). Table 4 sets out the 10 most frequently inappropriately 
prescribed items according to each of these groups. The number of 
potentially inappropriately prescribed items per prescriber group 
differed significantly (p<0.001). This association, however, was weak 
(Cramér’s V=0.09). Of the 102 items listed in the 2012-Beers criteria 
that were available in SA at the time of the study, a total of 84 were 
prescribed and identified in the study. Of these 84 items, 71 were 
prescribed most frequently by general practitioners, followed by 
pharmacists with 7 items, specialists with 3 items and psychiatric 
professionals with 3 items (under prescriber group ‘other’).
Discussion
Older patients often have multiple diseases requiring multiple 
drugs.[3] Polypharmacy increases the potential for the prescribing of 
potentially inappropriate medications.[3] The prevalence of PIPs in 
our study (13.0%) was found to be lower than that in international 
studies (ranging from 20% to 40%)[7,8] and that found by Chetty and 
Gray[9] in SA public sector primary healthcare facilities and old-age 
homes in 2004. However, similar to our study, the screening tool 
used by Chetty and Gray was adjusted based on the availability of 
data collected and the list of drugs obtainable in SA. In our study, 
only 102 of the 143 2012-Beers criteria items were available in SA 
at the time of the study. These results underscore the importance of 
adapting the Beers criteria list or developing a country-specific list 
to fit the needs of a prescribing measure in older adults in the SA 
health sector.
The rate of inappropriate prescribing is generally higher in women 
than in men,[9] in accordance with a higher prescription claim rate 
per female patient. Similarly, in our study women tended to receive 
more inappropriate medicine items than men; however, we found 
no difference between the sexes in terms of the average number of 
prescriptions per patient or the average number of items prescribed 
per patient, which could have influenced this association. Further 
studies are therefore needed in the SA private health sector to clarify 
the dynamics of sex differences in interactions between healthcare 
providers and patients resulting in women being prescribed more 
medication.
Studies assessing inappropriate prescribing report that the 
most common potentially inappropriate medicine items include 
amitriptyline, benzodiazepines, doxazosin, proton-pump inhibitors, 
NSAIDs, digoxin, antihistamines and oestrogen. In agreement 
with these studies, the most frequent potentially inappropriate 
medicine items prescribed for our population included oestrogen 
(oral and patch formulations), followed by non-steroidal anti-
inflammatory drugs, meprobamate and/or combinations thereof, 
amitriptyline and/or combinations, alprazolam, sliding-scale insulin, 
amiodarone and doxazosin. The prescribing of oestrogen (oral 
and patch formulations) among patients in our population was 
significantly higher in women than in men, whereas for both 
sliding-scale insulin and doxazosin, men received significantly more 
prescriptions than women. Oestrogen is essentially used as hormone 
replacement therapy (HRT) in women with oestrogen deficiency and 
to ameliorate hot flushes and atrophic changes in the urogenital tract. 
It is also indicated for preventing bone loss and the development of 
osteoporosis, and may reduce the risk of coronary artery disease, 
memory loss and Alzheimer’s disease.[12] In men, oestrogen is used for 
the treatment of low oestradiol (E2) levels from congenital aromatase 
deficiency. E2 can furthermore be used to relieve hot flushes in men 
treated with luteinising hormone-releasing hormone.[12,13] According 
to the position statement by the South African Menopause Society,[14] 
HRT can be prescribed for long-term use, and need not be routinely 
stopped within 5 years or by age 65 years, provided the patient 
has no untoward complications and continues to be monitored 
appropriately. However, since the prescription data analysed in 
this study contained no clinical indicators, it was not possible to 
determine whether medicines were prescribed without appropriate 
indications or whether existing clinical conditions may have provided 
reasons for, or against, the choices exercised.
The longevity of older adults is associated with musculoskeletal 
disorders that include osteoarthritis, rheumatoid arthritis (RA) and 
Table 2. Prevalence of potentially inappropriate drugs prescribed for the study population
Total study 
population Female Male p-value Effect size
Total potentially inappropriate drugs, n (%) 562 852 371 958 (66.1) 190 894 (33.9) <0.001 0.06*
Number of potentially inappropriate drugs per patient, mean (SD) (95% CI)
Gender 2.41 (1.62)
(2.40 - 2.43)
2.52 (1.69)
(2.51 - 2.54)
2.25 (1.52)
(2.23 - 2.27)
<0.001 0.16†
Age group (yr) <0.001
65≥ age ≤68 (n=16 124) 2.52 (1.74)
(2.50 - 2.55)
2.64 (1.80)
(2.61 - 2.68)
2.36 (1.63)
(2.32 - 2.40)
0.16†
68< age ≤72 (n=17 290) 2.45 (1.65)
(2.42 - 2.47)
2.57 (1.72)
(2.54 - 2.61)
2.26 (1.52)
(2.23 - 2.30)
0.18†
72< age ≤78 (n=19 526) 2.41 (1.61)
(2.38 - 2.43)
2.53 (1.68)
(2.50 - 2.57)
2.21 (1.47)
(2.18 - 2.25)
0.19†
Age >78 (n=18 266) 2.29 (1.51)
(2.26 - 2.31)
2.36 (1.55)
(2.34 - 2.39)
2.15 (1.43)
(2.12 - 2.19)
0.14†
*Cramér’s V statistic.
†Cohen’s d-value.
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Table 3. Prevalence of potentially inappropriate drug items identified in the study
Potentially inappropriate drug item
Total study 
population
(N)
Female,
n (%)
Male,
n (%) p-value Effect size*
Alprazolam 29 896 21 523 (72.0) 8 373 (28.0) <0.001 0.03
Amiodarone 17 433 7 579 (43.5) 9 854 (56.5) <0.001 0.09
Amitriptyline and combinations thereof 36 509 27 039 (74.1) 9 470 (25.9) <0.001 0.04
Aripiprazole 208 132 (63.5) 76 (36.5) 0.424 0.00
Aspirin and combinations thereof 5 447 2 818 (51.7) 2 629 (48.3) <0.001 0.03
Belladonna 2 2 (100.0) - 0.311 0.55†
Brompheniramine 21 11 (52.4) 10 (47.6) 0.185 0.00
Chlordiazepoxide and combinations thereof 3 926 2 957 (75.3) 969 (24.7) <0.001 0.02
Chlorpheniramine 12 668 7 369 (58.2) 5 299 (41.8) <0.001 0.03
Chlorpromazine 365 166 (45.5) 199 (54.5) <0.001 0.01
Clemastine 1 - 1 (100.0) 0.163 0.34†
Clomipramine 496 367 (74.0) 129 (26.0) <0.001 0.01
Clonazepam 5 372 3 663 (68.2) 1 709 (31.8) 0.001 0.00
Clonidine 70 70 (100.0) - <0.001 0.01
Clozapine 297 203 (68.4) 94 (31.6) 0.409 0.00
Cyprohepatadine 289 168 (58.1) 121 (41.9) 0.004 0.00
Dexchlorpheniramine 5 605 3 444 (61.5) 2 161 (38.5) <0.001 0.01
Diazepam 4 395 2 778 (63.2) 1 617 (36.8) <0.001 0.01
Diclofenac 36 062 19 546 (54.2) 16 516 (45.8) <0.001 0.07
Dicyclomine and combinations thereof 880 536 (60.9) 344 (39.1) 0.001 0.00
Diphenhydramine and combinations thereof 11 171 6 177 (55.3) 4 994 (44.7) <0.001 0.03
Digoxin 11 761 5 567 (47.3) 6 194 (52.7) <0.001 0.06
Dipyridamole and combinations thereof 1 866 891 (47.8) 975 (52.2) <0.001 0.02
Disopyramide 179 112 (62.6) 67 (37.4) 0.321 0.00
Doxazosin 14 816 4 235 (28.6) 10 581 (71.4) <0.001 0.13
Doxylamine and combinations thereof 8 977 5 746 (64.0) 3 231 (36.0) <0.001 0.01
Ergot 866 603 (69.6) 263 (30.4) 0.027 0.00
Oestrogen and combinations thereof (oral and patch 
formulations)
69 894 69 845 (99.9) 49 (0.1) <0.001 0.27
Flecainide 1 761 899 (51.0) 862 (49.0) <0.001 0.02
Fluphenazine 39 22 (56.4) 17 (43.6) 0.202 0.00
Flurazepam 125 76 (60.8) 49 (39.2) 0.212 0.00
Glibenclamide 9 409 3 724 (39.6) 5 685 (60.4) <0.001 0.07
Haloperidol 549 357 (65.0) 192 (35.0) 0.601 0.00
Hydroxyzine 1 813 1 249 (68.9) 564 (31.1) 0.012 0.00
Hyoscine and combinations thereof 7 492 4 832 (64.5) 2 660 (35.5) 0.003 0.00
Ibuprofen and combinations thereof 34 162 19 649 (57.5) 14 513 (42.5) <0.001 0.05
Imipramine 2 561 1 863 (72.8) 698 (27.2) <0.001 0.01
Indomethacin 3 611 2 361 (65.4) 1 250 (34.6) 0.372 0.00
Insulin (sliding scale) 18 715 6 966 (37.2) 11 749 (62.8) <0.001 0.11
Ketoprofen 1 464 922 (63.0) 542 (37.0) 0.012 0.00
Ketorolac 2 671 1 524 (57.1) 1 147 (42.9) <0.001 0.01
Lorazepam 10 615 7 483 (70.5) 3 132 (29.5) <0.001 0.01
Loxapine 9 9 (100.0) - 0.032 0.00
Continued ...
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osteoporosis. According to Usenbo et al.,[15] the prevalence of RA in 
SA for adults aged ≥65 years is relatively low at 2.5% in urban settings 
and 0.07% in rural settings; however, that for osteoarthritis is 55.1% 
in urban settings and ranges from 29.5% to 82.4% in rural settings. 
NSAIDs are effective in controlling pain and stiffness and are often 
prescribed on a long-term basis for patients with RA. Meloxicam, a 
cyclo-oxygenase (COX) inhibitor with antipyretic, anti-inflammatory 
and analgesic activity, has been approved by the US Food and Drug 
Administration for use in osteoarthritis. Diclofenac is a COX-2 
selective inhibitor that is effective for pain relief and the prevention 
and alleviation of fever, and to reduce inflammation. It is also useful 
to treat RA, osteoarthritis and ankylosing spondylitis. Ibuprofen is 
useful in the treatment of RA and osteoarthritis, and may also be 
used to alleviate moderate pain. It is therefore not surprising that a 
significant proportion (19.8%) of patients in our study population 
received NSAIDs, in particular meloxicam, diclofenac and ibuprofen.
Table 3. (continued) Prevalence of potentially inappropriate drug items identified in the study
Potentially inappropriate drug item
Total study 
population
(N)
Female,
n (%)
Male,
n (%) p-value Effect size*
Mefenamic acid 1 121 714 (63.7) 407 (36.3) 0.091 0.00
Meloxicam 41 030 28 353 (69.1) 12 677 (30.9) <0.001 0.02
Meperidine 228 151 (66.2) 77 (33.8) 0.964 0.00
Meprobamate and combinations thereof 27 894 19 326 (69.3) 8 568 (30.7) <0.001 0.02
Methocarbamol 1 609 1 080 (67.1) 529 (32.9) 0.379 0.00
Methyldopa 3 950 2 862 (72.5) 1 088 (27.5) <0.001 0.01
Methyltestosterone 2 - 2 (100.0) 0.048 0.00
Metoclopramide 7 971 4 944 (62.0) 3 027 (38.0) <0.001 0.01
Naproxen 1 786 1 161 (65.0) 625 (35.0) 0.335 0.00
Nifedipine 465 304 (65.4) 161 (34.6) 0.747 0.00
Nitrofurantoin 4 296 3 619 (84.2) 677 (15.8) <0.001 0.03
Olanzapine 1 871 1 316 (70.3) 555 (29.7) <0.001 0.01
Orphenadrine and combinations thereof 4 371 2 730 (62.5) 1 641 (37.5) <0.001 0.01
Oxazepam 11 732 8 527 (72.7) 3 205 (27.3) <0.001 0.02
Paliperidone 10 10 (100.0) - 0.024 0.00
Pentazocine 9 5 (55.6) 4 (44.4) 0.505 0.00
Phenobarbitone 697 409 (56.7) 288 (41.3) <0.001 0.01
Pimozide 35 32 (91.4) 3 (8.6) 0.002 0.00
Piroxicam 4 221 2 586 (61.3) 1 635 (38.7) <0.001 0.01
Prazosin 977 458 (46.9) 519 (53.1) <0.001 0.02
Promethazine and combinations thereof 3 727 2 324 (62.4) 1 403 (37.6) <0.001 0.01
Propafenone 540 269 (49.8) 271 (50.2) <0.001 0.01
Propantheline 74 59 (79.7) 15 (20.3) 0.013 0.00
Quetiapine 4 977 3 268 (65.7) 1 709 (34.3) 0.527 0.00
Reserpine 454 344 (75.8) 110 (24.2) <0.001 0.01
Risperidone 6 873 4 378 (63.7) 2 495 (36.3) <0.001 0.01
Sotalol 1 736 890 (51.3) 846 (48.7) <0.001 0.02
Spironolactone 3 260 1 780 (54.6) 1 480 (45.4) <0.001 0.02
Temazepam 2 393 1 516 (63.4) 877 (36.6) 0.005 0.00
Terazosin 250 23 (9.2) 227 (90.8) <0.001 0.03
Testosterone 290 10 (3.5) 280 (96.5) < 0.001 0.03
Triazolam 1 774 1 104 (62.2) 670 (37.8) 0.001 0.01
Trifluoperazine 168 136 (81.0) 32 (19.0) < 0.001 0.01
Trimipramine 706 505 (71.5) 201 (28.5) 0.002 0.00
Triprolidine and combinations thereof 1 158 635 (54.8) 523 (45.2) < 0.001 0.01
Ziprasidone 114 87 (76.3) 27 (23.7) 0.021 0.00
Zolpidem 0 - -
*All values are Cramér’s V statistics, except where clearly stated otherwise.
†Fisher’s exact test.
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Approximately 1 in 15 patients (male/female ratio 1:3) in our 
study population received amitriptyline or combinations thereof. A 
further 5% of patients received alprazolam. According to the South 
African Stress and Health (SASH) study[16] the lifetime disorders 
most frequently encountered by South Africans are anxiety disorder 
(15.8%), drug use disorders (13.3%) and mood disturbances (9.8%). 
Antidepressant medication such as amitriptyline is mainly used 
for the treatment of depression; however, its off-label use includes 
indications such as insomnia, panic disorders, alcohol dependence, 
pain management, and agitation in patients with dementia.[17] 
Benzodiazepines are essentially used to treat acute anxiety conditions 
and as hypnotics,[12] and are frequently prescribed for older persons, 
in particular females.
A substantial number of meprobamate-containing items were 
prescribed for older patients in our study population. Analgesics, 
in general, are one of the most frequently prescribed drug groups, 
particularly to women. Earlier studies conducted in SA indicated 
that the second and third most frequently prescribed analgesics 
were combinations of drugs of which meprobamate formed part 
of the combination.[18] Women in these studies received analgesics 
containing meprobamate nearly five times more often than men, 
whereas in our study, women were about three times more likely to 
receive analgesics containing meprobamate.
Men received significantly more prescriptions than women for 
both sliding-scale insulin and doxazosin. Insulin is indicated for 
the treatment of type 1 diabetes mellitus and as a supplement in 
type 2 diabetes. According to the South African National Health 
and Nutrition Examination Survey (SANHANES-1), ~19% of older 
patients (≥65 years) in the country had a diagnosis of diabetes in 
2012.[19] At a national level, mean glycosylated haemoglobin (HbA1c) 
levels increased significantly with age, reaching their highest value in 
the group 55 - 64 years of age. Among men in particular, the increase 
in mean HBA1c values was associated with a significantly higher age-
related prevalence of impaired glucose homeostasis (HBA1c >6.1% 
and <6.5%) and diabetes (HBA1c >6.5%), with the highest prevalence 
in the groups aged ≥65 years and 55 - 64 years (19.7% and 20.9%, 
respectively).
Benign prostatic hypertrophy (BPH) can be classified as a common 
urological condition that increases with age. BPH affects 40% of 
men in their 50s, with an increase in prevalence to 80% of men in 
their 70s. Medical therapy generally includes alpha-blockers such as 
doxazosin.[12] It is therefore conceivable that the men in our study 
population received more prescriptions for doxazosin than their 
female counterparts.
Similar to the trend that has been observed in other studies, the 
potentially inappropriate items in our study were prescribed most 
frequently by general practitioners. It is not clear why we observed 
this trend; however, as noted by Chetty and Gray,[9] the Beers criteria 
are limited in both sensitivity and specificity, as these criteria do 
not take into account the individualisation of medicine regimens by 
prescribers to suit individual patients’ needs.
Other factors to consider when interpreting our findings include 
the use of only one PBM’s data, so only members of the medical aid 
schemes administered by the selected PBM were represented in the 
study. The database furthermore only included claims for medicine 
items and not for other medical devices and interventions. Patients 
may also have gone in and out of eligibility, which could have led to 
subjects and data being missed, with subsequent under-reporting of 
PIPs.
Conclusions
Our study showed that PIPs according to explicit criteria were 
common in older patients registered on the database. In this study, 
women were more likely to be exposed to PIPs than their male 
counterparts. Although it is important to remember that the use of 
explicit criteria cannot substitute for clinical judgement based on the 
individual patient, there is a need for a prescribing measure for older 
adults in the SA health sector that can be used to encourage value-
driven healthcare.
Acknowledgements. The authors would like to thank Ms A Bekker for 
assistance with the initial data extraction from the database and Ms E 
Blaauw for language editing.
Compliance with ethical standards. No sources of funding were used to 
assist with the preparation of this manuscript. The study was conducted 
with the approval of the Health Research Ethics Committee of North-West 
University (Potchefstroom campus) (NWU-00179-14-S1) and the board 
Table 4. Prevalence of the 10 most inappropriately prescribed drugs per prescriber group
Total study 
population
(N)
GPs,
n (%)
Pharmacy,
n (%)
Specialists,
n (%)
Other,
n (%) p-value Effect size*
Beers criteria item <0.001 0.09
Alprazolam 29 896 24 073 (80.5) - 4 536 (15.2) 1 287 (4.3)
Amiodarone 17 433 9 820 (56.3) - 7 324 (42.0) 289 (1.7)
Amitriptyline and combinations thereof 36 509 28 095 (77.0) - 6 793 (18.6) 1 621 (4.4)
Diclofenac 36 062 22 205 (61.6) 10 200 (28.3) 2 732 (7.6) 925 (2.6)
Doxazosin 14 816 10 499 (70.9) 1 (0.0) 4 109 (27.7) 207 (1.4)
 Oestrogen and combinations thereof 
(oral and patch formulations)
69 894 56 978 (81.5) 106 (0.2) 11 368 (16.3) 1 442 (2.1)
Ibuprofen 34 162 16 347 (47.9) 12 351 (36.2) 2 312 (6.8) 3 152 (9.2)
Insulin (sliding scale) 18 715 11 971 (64.0) - 6 492 (34.7) 252 (1.3)
Meloxicam 41 030 34 544 (84.2) - 5 765 (14.1) 721 (1.8)
Meprobamate and combinations thereof 27 894 21 956 (78.7) 71 (0.3) 4 447 (15.9) 1 420 (5.1)
GPs = general practitioners.
*All values are Cramér’s V statistics.
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